Published Studies Related to Cosopt (Dorzolamide / Timolol Ophthalmic)
[Comparative study of the pressure lowering efficacy and variations in the ocular pulse amplitude between fixed combinations of dorzolamide/timolol and brinzolamide/timolol]. [2011.05]
OBJECTIVE: To determine possible differences in the intraocular pressure (IOP) and ocular pulse amplitude (OPA) lowering capacity of the fixed drug combinations dorzolamide/timolol and brinzolamide/timolol... CONCLUSIONS: Both fixed combinations were similarly effective in reducing intraocular pressure and ocular pulse amplitude. Adverse effects related to both treatments were mild and well-tolerated, though itching occurred most frequently in the eyes treated with dorzolamide/timolol. Copyright (c) 2011 Sociedad Espanola de Oftalmologia. Published by Elsevier Espana. All rights reserved.
Comparison of the efficacy and tolerability of preservative-free and preservative-containing formulations of the dorzolamide/timolol fixed combination (COSOPT) in patients with elevated intraocular pressure in a randomized clinical trial. [2010.12]
BACKGROUND: The aim of this study was to compare the efficacy and tolerability of preservative-free (PF) and preservative-containing (PC) formulations of the dorzolamide/timolol fixed combination (COSOPT) in patients with elevated intraocular pressure (IOP)... CONCLUSIONS: In patients with elevated IOP, PF and PC dorzolamide/timolol were equivalent in efficacy for change in trough and peak IOP, and had generally similar tolerability.
Comparison of ocular hypotensive actions of fixed combinations of brimonidine/timolol and dorzolamide/timolol. [2010.07]
OBJECTIVE: To compare brimonidine/timolol fixed combination (BrTFC; Combigan *) with dorzolamide/timolol fixed combination (DTFC; Cosopt dagger) in terms of ability to lower intraocular pressure (IOP) in primary open-angle glaucoma (POAG)... CONCLUSION: Reductions from baseline in mean diurnal IOP and morning IOP were greater with BrTFC than with DTFC.
Efficacy and safety of fixed combinations of latanoprost/timolol and dorzolamide/timolol in open-angle glaucoma or ocular hypertension. [2010.07]
AIMS: To compare intraocular pressure (IOP) reductions with fixed-combination (FC) latanoprost/timolol once daily in the evening vsFC dorzolamide/timolol twice daily... CONCLUSIONS: When beta-blocker therapy is inadequate, either FC may achieve the desired IOP level, but FC latanoprost/timolol more often achieves a pressure of <or=16 mm Hg. Both FCs were well tolerated.
Additive intraocular pressure reduction effect of fixed combination of maleate timolol 0.5%/dorzolamide 2% (Cosopt) on monotherapy with latanoprost (Xalatan) in patients with elevated intraocular pressure: a prospective, 4-week, open-label, randomized, controlled clinical trial. [2010.06]
PURPOSE: To evaluate the additive effect of dorzolamide/timolol fixed combination in patients under monotherapy with latanoprost... CONCLUSIONS: In our sample, dorzolamide 2%/timolol 0.5% fixed combination as add-on therapy in patients with open-angle glaucoma or ocular hypertension under monotherapy with latanoprost with IOP already in mid-teens levels may further enhance pressure reduction.
Clinical Trials Related to Cosopt (Dorzolamide / Timolol Ophthalmic)
Effects of Cosopt on IOP and on Ocular Diastolic Perfusion Pressure [Not yet recruiting]
Hypothesis: Studies suggest that patients with low diastolic velocity and high resistivity
index in the ophthalmic artery had more progressive visual fields, the investigators
hypothesize therefore that addition of Cosopt to Latanoprost could improve ocular
diastolic perfusion pressure (ODPP).
Objective: To evaluate the effects of Cosopt on ODPP in patients not adequately controlled
with latanoprost alone.
The Effects of Cosopt® Vs Xalacom® on Ocular Hemodynamics and Intraocular Pressure (IOP) in Primary Open-angle Glaucoma (POAG) [Recruiting]
Both Cosopt® and Xalatan® plus Timoptic® will significantly lower IOP, however only Cosopt®
will demonstrate positive hemodynamic effects. The clinical significance of this will be
investigated by examining the ophthalmic and short posterior ciliary arteries to determine
the blood supply to the optic nerve head, the site of damage in glaucoma
Intraocular Pressure and Ocular Perfusion Pressure of Cosopt in Normal Tension Glaucoma [Recruiting]
To prove the non-inferiority of the fixed timolol-dorzolamide combination (Cosopt) compared
to 0. 005% latanoprost (Xalatan) in the aspects of intraocular pressure (IOP) and ocular
perfusion pressure (OPP) in subjects with normal tension glaucoma (NTG)
Clinical hypotheses. Primary hypothesis
- Cosopt group is non-inferior to Xalatan group in diurnal IOP reduction.
- Cosopt group is non-inferior to Xalatan group in diurnal diastolic and systolic OPP.
Patient Preference Comparison of AZARGA Versus COSOPT [Recruiting]
The purpose of this study is to assess patient preference of AZARGA® compared to COSOPT®
after one week instillation of each study medication is administered to both eyes in
patients with open-angle glaucoma or ocular hypertension.
Comparison of Efficacy of Two Groups of Glaucoma Drops (Xalatan vs.Cosopt) in Reducing Eye Pressure Following Laser (SLT)Treatment in the Management of Glaucoma. [Recruiting]
WHAT IS THIS STUDY ABOUT? Glaucoma and ocular hypertension are chronic eye diseases that can
damage the optic nerve and lead to vision loss or blindness. The optic nerve acts like an
electric cable with over a million wires. This nerve is responsible for carrying images
from the eye to the brain. The way glaucoma and ocular hypertension cause blindness depends
on many factors, but the most important factor is the increased pressure inside the eye
There is no cure for glaucoma or ocular hypertension. However, lowering the pressure inside
the eye has been shown to slow the progression of disease. Intraocular pressure can be
lowered by glaucoma medication, laser treatment, or surgery.
You have open angle glaucoma, pseudoexfoliative glaucoma, or ocular hypertension.
Researchers want to find out more about how 2 drugs called Cosopt (dorzolamide hydrochloride
and timolol maleate) and Xalatan (latanoprost) can help people with these conditions.
Cosopt and Xalatan are both eye drops that are approved by the U. S. Food and Drug
Administration (FDA) to reduce intraocular pressure in people with open angle glaucoma and
The study doctor will do a laser procedure called Selective Laser Trabeculoplasty (SLT) on
people in this study to help lower their intraocular pressure. The FDA has approved SLT to
treat open angle glaucoma and ocular hypertension.
Then the study doctor will ask some participants to use either Cosopt or Xalatan, if their
intraocular pressure is still too high 4 to 6 weeks after the SLT procedure. The study
doctor wants to see which of the 2 study drugs (Cosopt or Xalatan) is better at reducing
intraocular pressure after SLT.
It is planned that about 30 people with glaucoma or ocular hypertension who are at least 18
years old will be in this study. Out of the participants whose intraocular pressure is
still too high after SLT, half will use Cosopt and half will use Xalatan. You do not have
to be in this study to have SLT or to use Cosopt or Xalatan.
Reports of Suspected Cosopt (Dorzolamide / Timolol Ophthalmic) Side Effects
Ocular Hyperaemia (12),
Loss of Consciousness (6),
Drug Ineffective (5),
Intraocular Pressure Increased (5),
Heart Rate Irregular (5),
Feeling Cold (4), more >>